Clasp Therapeutics是一家总部位于美国马萨诸塞州的生物技术公司，致力于开发针对每位患者免疫系统的模块化T细胞诱导体（TCE），这些TCE针对常见的 ...

Clasp's pHLAre™ platform is optimized for tumor-specific antigens, with the potential to yield safer and more effective precision immunotherapies - Preclinical data presented at the 2025 ...

Clasp seeks to prevent that toxicity by instead targeting oncogenes such as p53, KRAS, and PI3 Kinase, which are central to the tumor’s oncogenicity. Aside from their main roles, these oncogenes ...

Clasp Therapeutics has burst onto the T-cell engager (TCE) scene with $150 million in funding for a platform that aims to improve the safety of the class, which is currently gaining traction in ...